• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Diphenylethers

Professional Introduction to 4-Methyl-2-phenoxyaniline (CAS No: 60287-69-6)

4-Methyl-2-phenoxyaniline, with the chemical formula C₈H₁₁NO and CAS number 60287-69-6, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This aromatic amine derivative exhibits a unique structural configuration that makes it a valuable intermediate in the synthesis of various bioactive molecules. The presence of both methyl and phenoxy groups in its molecular framework contributes to its diverse chemical reactivity and potential applications in drug development.

The compound's structure, characterized by a phenyl ring substituted with a methyl group at the 4-position and a phenoxy group at the 2-position, endows it with specific electronic and steric properties. These properties are crucial for its role as a building block in organic synthesis, particularly in the preparation of more complex molecules such as pharmaceuticals and agrochemicals. The amine functionality further enhances its utility, allowing for further derivatization through reactions like acylation, alkylation, and condensation.

In recent years, 4-Methyl-2-phenoxyaniline has garnered attention due to its potential applications in the development of novel therapeutic agents. Research studies have highlighted its role as a precursor in the synthesis of kinase inhibitors, which are pivotal in treating various forms of cancer and inflammatory diseases. The compound's ability to interact with biological targets at the molecular level has been explored in several preclinical studies, demonstrating its promise as a lead compound for further drug discovery efforts.

One of the most intriguing aspects of 4-Methyl-2-phenoxyaniline is its versatility in medicinal chemistry. Its structural features allow for modifications that can fine-tune its pharmacological properties, making it adaptable for targeting different disease mechanisms. For instance, researchers have investigated its derivatives as potential antimicrobial agents, leveraging its aromatic system to disrupt bacterial cell wall synthesis. This adaptability underscores the compound's significance as a versatile scaffold in drug design.

The synthesis of 4-Methyl-2-phenoxyaniline typically involves multi-step organic reactions, often starting from readily available aromatic precursors. Advanced synthetic methodologies have been developed to improve yield and purity, ensuring that the final product meets the stringent requirements of pharmaceutical applications. Techniques such as catalytic hydrogenation, nucleophilic substitution, and palladium-catalyzed cross-coupling reactions are commonly employed in these processes.

The pharmacological profile of 4-Methyl-2-phenoxyaniline has been extensively studied in vitro and in vivo. Preliminary findings suggest that it exhibits moderate affinity for certain protein targets, which could translate into therapeutic effects upon appropriate dosing and formulation. However, further research is necessary to fully elucidate its mechanism of action and optimize its pharmacokinetic properties. This includes evaluating its metabolic stability, distribution patterns, and potential side effects.

In the context of current pharmaceutical research, 4-Methyl-2-phenoxyaniline represents an example of how structural diversity can be leveraged to develop innovative treatments. Its unique combination of functional groups provides a rich platform for medicinal chemists to explore new chemical space. By understanding its reactivity and interaction patterns with biological systems, researchers can design more effective drugs with improved efficacy and reduced toxicity.

The regulatory landscape for compounds like 4-Methyl-2-phenoxyaniline is governed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory bodies ensure that all pharmaceutical intermediates used in drug development meet rigorous safety and quality standards before they can be advanced into clinical trials. Compliance with these regulations is essential for ensuring the safety of patients who may eventually benefit from drugs derived from such compounds.

The future prospects for 4-Methyl-2-phenoxyaniline are promising, given its potential as a key intermediate in drug discovery. As research continues to uncover new therapeutic applications and synthetic strategies, this compound is likely to remain a cornerstone in medicinal chemistry efforts worldwide. Collaborative research initiatives involving academic institutions, pharmaceutical companies, and biotechnology firms will be crucial in realizing this potential fully.

In conclusion, 4-Methyl-2-phenoxyaniline (CAS No: 60287-69-6) is a multifaceted compound with significant implications for pharmaceutical research and development. Its unique structural features make it an invaluable tool for synthesizing bioactive molecules targeting various diseases. With ongoing studies exploring its pharmacological properties and synthetic applications, this compound continues to play a vital role in advancing our understanding of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)